The minimal effective exemestane dose for endocrine activity in advanced breast cancer

被引:41
作者
Bajetta, E
Zilembo, N
Noberasco, C
Martinetti, A
Mariani, L
Ferrari, L
Buzzoni, R
Greco, M
Bartoli, C
Spagnoli, I
Danesini, GM
Artale, S
Paolini, J
机构
[1] IST NAZL STUDIO & CURA TUMORI,DIV NUCL MED,I-20133 MILAN,ITALY
[2] IST NAZL STUDIO & CURA TUMORI,DIV STAT & BIOMETRY,I-20133 MILAN,ITALY
[3] IST NAZL STUDIO & CURA TUMORI,DIV SURG 4,I-20133 MILAN,ITALY
[4] IST NAZL STUDIO & CURA TUMORI,DIV RADIOL A,I-20133 MILAN,ITALY
[5] PHARMACIA & UPJOHN INC,I-20151 MILAN,ITALY
关键词
breast cancer; advanced disease; hormonotherapy; aromatase inhibitor; postmenopause;
D O I
10.1016/S0959-8049(96)00494-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phase I studies have demonstrated that exemestane, an irreversible oral aromatase inhibitor, is able to suppress circulating oestrogen levels. In our previous experience, doses ranging from 2.5 to 25 mg induced a similar suppression of oestrogens. The aim of this study was to identify the minimum effective exemestane dose on the basis of endocrine activity. 20 evaluable postmenopausal advanced breast cancer patients were randomly given exemestane 0.5, 1, 2.5 or 5 mg, in double-blind conditions. Oestrone (E1), oestradiol (E2), oestrone sulphate (E1S), gonadotrophins, sex-hormone binding globulin and dehydroepiandrosterone sulphate serum levels were evaluated from the first day of treatment to the 7th, 14th, 28th and 56th day. Serum E1, E2 and E1S levels were suppressed by all doses starting from day 7; the degree of inhibition versus baseline was 25 up to 72% for E1, 30 up to 62% for E2 and 16 up to 52% for E1S, with higher doses achieving greater suppression; these changes were maintained over time. A significant increase in FSH and LH levels was observed for all doses. Treatment tolerability was satisfactory. The endocrine effects of exemestane appear to be dose related and 0.5 and 1 mg are ineffective for adequately suppressing circulating oestrogens. (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:587 / 591
页数:5
相关论文
共 23 条
  • [1] ENDOCRINOLOGIC AND CLINICAL-EVALUATION OF 2 DOSES OF FORMESTANE IN ADVANCED BREAST-CANCER
    BAJETTA, E
    ZILEMBO, N
    BUZZONI, R
    NOBERASCO, C
    DILEO, A
    BARTOLI, C
    MERSON, M
    SACCHINI, V
    MOGLIA, D
    CELIO, L
    NELLI, P
    [J]. BRITISH JOURNAL OF CANCER, 1994, 70 (01) : 145 - 150
  • [2] COOMBES RC, 1992, EUR J CANCER, V28A, P1941
  • [3] AROMATASE INHIBITION AND EXPERIMENTAL ANTITUMOR-ACTIVITY OF FCE-24304, MDL-18962 AND SH-489
    DISALLE, E
    BRIATICO, G
    GIUDICI, D
    ORNATI, G
    ZACCHEO, T
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1989, 34 (1-6) : 431 - 434
  • [4] A COMPARISON OF THE ENDOCRINE EFFECTS OF LOW-DOSE AMINOGLUTETHIMIDE WITH AND WITHOUT HYDROCORTISONE IN POSTMENOPAUSAL BREAST-CANCER PATIENTS
    DOWSETT, M
    HARRIS, AL
    STUARTHARRIS, R
    HILL, M
    CANTWELL, BMJ
    SMITH, IE
    JEFFCOATE, SL
    [J]. BRITISH JOURNAL OF CANCER, 1985, 52 (04) : 525 - 529
  • [5] DOWSETT M, 1989, CANCER RES, V49, P1306
  • [6] EVANS TRJ, 1992, CANCER RES, V52, P5933
  • [7] METABOLISM OF THE AROMATASE INHIBITOR 4-HYDROXYANDROSTENEDIONE INVIVO - IDENTIFICATION OF THE GLUCURONIDE AS A MAJOR URINARY METABOLITE IN PATIENTS AND BILIARY METABOLITE IN THE RAT
    GOSS, PE
    JARMAN, M
    WILKINSON, JR
    COOMBES, RC
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1986, 24 (02) : 619 - 622
  • [8] GOSS PE, 1986, CANCER RES, V46, P4823
  • [9] SOURCE OF ESTROGEN PRODUCTION IN POSTMENOPAUSAL WOMEN
    GRODIN, JM
    SIITERI, PK
    MACDONALD, PC
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1973, 36 (02) : 207 - 214
  • [10] HARRIS AL, 1986, BREAST CANCER RES TR, V7, P41